Immix Biopharma (IMMX)
(Delayed Data from NSDQ)
$1.81 USD
-0.04 (-2.16%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $1.81 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Immix Biopharma, Inc. (IMMX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.00 | $7.00 | $7.00 | 278.38% |
Price Target
Only one analyst offered a short-term price target of $7.00 for Immix Biopharma, Inc. This represents an increase of 278.38% from the last closing price of $1.85.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Strong Buy-equivalent recommendation for Immix Biopharma, Inc. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 1.00 a month ago based on just one Strong Buy recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | NA |
Buy | 0 | 0 | 0 | 0 | NA |
Hold | 0 | 0 | 0 | 0 | NA |
Sell | 0 | 0 | 0 | 0 | NA |
Strong Sell | 0 | 0 | 0 | 0 | NA |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | NA |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/1/2024 | H.C. Wainwright & Co. | Robert Burns | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 1 |
Average Target Price | $7.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.16 |
IMMX FAQs
Immix Biopharma, Inc. (IMMX) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 1 brokerage firms.
The average price target for Immix Biopharma, Inc. (IMMX) is $7.00. The current on short-term price targets is based on 2 reports.
The forecasts for Immix Biopharma, Inc. (IMMX) range from a low of $7 to a high of $7. The average price target represents a increase of $278.38 from the last closing price of $1.85.
The current UPSIDE for Immix Biopharma, Inc. (IMMX) is 278.38%
Only one analyst offered a short-term price target of $7.00 for Immix Biopharma, Inc. This represents an increase of 278.38% from the last closing price of $1.85.